Syneos Health (FRA:8IN) Debt-to-Asset : 0.36 (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Syneos Health Debt-to-Asset?

Syneos Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €63 Mil. Syneos Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €2,609 Mil. Syneos Health's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was €7,454 Mil. Syneos Health's debt to asset for the quarter that ended in Jun. 2023 was 0.36.

Syneos Health Debt-to-Asset Historical Data

The historical data trend for Syneos Health's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health Debt-to-Asset Chart

Syneos Health Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.39

0.40

0.37

0.35

Syneos Health Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Asset	Get a 7-Day Free Trial															0.38	0.37	0.35	0.36	0.36

Competitive Comparison of Syneos Health's Debt-to-Asset

For the Diagnostics & Research subindustry, Syneos Health's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syneos Health's Debt-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Syneos Health's Debt-to-Asset falls into.

Syneos Health Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Syneos Health's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(64.187	+	2672.33)	/	7740.062
	=	0.35

Syneos Health's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(63.017	+	2609.276)	/	7453.577
	=	0.36

Syneos Health (FRA:8IN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Syneos Health Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Syneos Health's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Syneos Health (FRA:8IN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (FRA:8IN) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1030 Sync Street, Morrisville, NC, USA, 27560-5468

Website

https://www.syneoshealth.com

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Syneos Health (FRA:8IN) Headlines

No Headlines